Your browser doesn't support javascript.
loading
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
Franzetti, Marco; Pozzetti, Ugo; Carugati, Manuela; Pandolfo, Alessandro; Molteni, Chiara; Faccioli, Paolo; Castaldo, Gioacchino; Longoni, Ernesto; Ormas, Valentina; Iemoli, Enrico; Piconi, Stefania.
Afiliación
  • Franzetti M; Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy. Electronic address: m.franzetti@asst-lecco.it.
  • Pozzetti U; Medicine Department, A. Manzoni Hospital, Lecco, Italy.
  • Carugati M; Division of Infectious Diseases, Duke University, Durham, United States; ATS Brianza, Lecco, Italy.
  • Pandolfo A; Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy.
  • Molteni C; Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy.
  • Faccioli P; Radiology Unit, Alessandro Manzoni Hospital, Lecco, Italy.
  • Castaldo G; Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy.
  • Longoni E; Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy.
  • Ormas V; Intensive Care Unit, Manzoni Hospital, Lecco, Italy.
  • Iemoli E; First Infectious Diseases Department and Allergy and Clinical Immunology Unit, L. Sacco Hospital, Milan, Italy.
  • Piconi S; Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy.
Int J Infect Dis ; 97: 215-218, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32422376
We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Insuficiencia Respiratoria / Adenosina Monofosfato / Receptores de Interleucina-1 / Infecciones por Coronavirus / Alanina / Proteína Antagonista del Receptor de Interleucina 1 / Betacoronavirus Límite: Humans / Male / Middle aged Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article Pais de publicación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Insuficiencia Respiratoria / Adenosina Monofosfato / Receptores de Interleucina-1 / Infecciones por Coronavirus / Alanina / Proteína Antagonista del Receptor de Interleucina 1 / Betacoronavirus Límite: Humans / Male / Middle aged Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article Pais de publicación: Canadá